VBI Vaccines to Participate in the 32nd Annual Oppenheimer Healthcare ConferenceBusiness Wire • 03/15/22
VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/07/22
VBI Vaccines Reports Fourth Quarter and Full Year Financial Results for 2021, Provides Corporate Update and Outlook for 2022Business Wire • 03/07/22
VBI Vaccines Receives Positive CHMP Opinion for 3-Antigen Hepatitis B Vaccine for Immunization Against Hepatitis B Infection in Adults in the European UnionBusiness Wire • 02/25/22
VBI Vaccines Announces PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in AdultsBusiness Wire • 02/23/22
VBI Vaccines to Participate in the B. Riley Securities 2022 Oncology Investor ConferenceBusiness Wire • 01/26/22
VBI Vaccines Announces Dosing of First Patient in Second Phase 2 Study in Chronic Hepatitis B Patients as Part of Expansion of Clinical Collaboration With Brii BioBusiness Wire • 01/05/22
VBI Vaccines Announces Filing of New Drug Submission for 3-Antigen Hepatitis B Vaccine to Health CanadaBusiness Wire • 12/09/21
VBI Vaccines Reveals Updated Overall Survival Data From Brain Cancer Vaccine TrialBenzinga • 12/02/21
VBI Vaccines to Present New Overall Survival Data from Phase 2a Study in Recurrent GBM at the World Vaccine & Immunotherapy Congress 2021Business Wire • 12/01/21
VBI Vaccines Announces FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in AdultsBusiness Wire • 12/01/21
VBI Vaccines Announces Third Quarter 2021 Financial Results and Provides Corporate UpdateBusiness Wire • 11/08/21
VBI Vaccines Announces e-Poster Presentation of 3-Antigen Prophylactic Hepatitis B Vaccine Data at The Liver Meeting® 2021Business Wire • 11/01/21
VBI Vaccines: Hepatitis Vaccine Approval Can Be A Catalyst For >$1bn ValuationSeeking Alpha • 10/31/21
Analysts Estimate VBI Vaccines, Inc. (VBIV) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/25/21
VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, CONSTANT, of VBI's Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Journal of the American Medical Association Network OpenBusiness Wire • 10/13/21
VBI Vaccines Announces New Preclinical Data and Initiation of VBI-2905 Clinical Study Targeting Broadened Immunity Against COVID-19 and Variants of ConcernBusiness Wire • 09/29/21
VBI Vaccines Announces Second Quarter 2021 Financial Results and Provides Corporate UpdateBusiness Wire • 08/02/21